Navidea Biopharmaceuticals has taken out a licensing agreement with Alseres Pharmaceuticals, Inc. The licensing agreement is for [123I]-E-IACFT Injection (CFT), an Iodine-123 radiolabeled imaging agent being developed as an aid in the diagnosis of Parkinson's disease and other movement disorders, with a potential use as a diagnostic aid in dementia. The agreement grants Navidea an exclusive, worldwide sub-license to research, develop and commercialise CFT, for which Alseres will earn a one-time sub-license execution payment equal to $175,000 and 300,000 shares of NAVB common stock.